A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 1, 2009, Pages 115-120

  Fotaki, N ^a   Aivaliotis, A ^a   Butler, J ^b   Dressman, J ^c   Fischbach, M ^c   Hempenstall, J ^b   Klein, S ^c   Reppas, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Dissolution; Extended release; Hydrodynamics; In vitro in vivo correlations; Modified release; Monolithic dosage forms; Release

Indexed keywords

ROSIGLITAZONE; SALBUTAMOL SULFATE;

ARTICLE; ASCENDING COLON; COMPARATIVE STUDY; CONTROLLED RELEASE FORMULATION; DIET RESTRICTION; DISTRIBUTION VOLUME; DRUG ELIMINATION; DRUG SOLUBILITY; EXTENDED RELEASE FORMULATION; HUMAN; HUMAN EXPERIMENT; HYDRODYNAMICS; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; OSMOTIC PUMP; PHYSICAL CHEMISTRY; SIMULATION; SINGLE DRUG DOSE; SMALL INTESTINE; STOMACH; VOLUNTEER;

ALBUTEROL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; HUMANS; THIAZOLIDINEDIONES;

EID: 68349158943     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.04.012     Document Type: Article

References (33)

1. FDA (Food and Drug Administration), Center for Drug Evaluation and Research (CDER), Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, 1997.
2. Uppoor V.R. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release 72 (2001) 127-132
3. Klein S., Stein J., and Dressman J. Site-specific release of anti-inflammatory drugs in the gastrointestinal tract: an in vitro model. J. Pharm. Pharmacol. 57 (2005) 709-720
4. Fotaki N., Symillides M., and Reppas C. In vitro vs. canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur. J. Pharm. Sci. 24 (2005) 115-122
5. E. Jantratid, V. De Maio, E. Ronda, V. Mattavelli, J. Dressman, In vitro correlation analysis of modified release diclofenac sodium pellets, AAPS Annual Meeting, San Diego CA, USA, 2007.
6. Klein S., Rudolph M.W., Skalsky B., Petereit H.U., and Dressman J.B. Use of the BioDis to generate a physiologically relevant IVIVC. J. Control. Release 130 (2008) 216-219
7. Fotaki N., Symillides M., and Reppas C. Canine vs. in vitro data for predicting input profiles of L-sulpiride after oral administration. Eur. J. Pharm. Sci. 26 (2005) 324-333
8. Rohrs B.R., Burch-Clark D.L., Witt M.J., and Stelzer D.J. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations. J. Pharm. Sci. 84 (1995) 922-926
9. Altaf S.A., Wong D., Gebert M., Larrabee S., Yu K., and Friend D.R. Drug release profiles of swellable hydrocolloid formulations: USP apparatus 2 versus apparatus 3, in vitro correlation. Pharm. Technol. 22 (1998) 62-70
10. Abrahamsson B., Roos K., and Sjögren J. Investigation of prandial effects on hydrophilic matrix tablets. Drug Dev. Ind. Pharm. 25 (1999) 765-771
11. Missaghi S., and Fassihi R. Release characterization of dimenhydrinate from an eroding and swelling matrix: selection of appropriate dissolution apparatus. Int. J. Pharm. 293 (2005) 35-42
12. Defang O., Shufang N., Wei L., Hong G., Hui L., and Weisan P. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev. Ind. Pharm. 31 (2005) 677-685
13. Garbacz G., Wedemeyer R.S., Nagel S., Giessmann T., Mönnikes H., Wilson C.G., Siegmund W., and Weitschies W. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. Eur. J. Pharm. Biopharm. 70 (2008) 421-428
14. Verma R.K., Mishra B., and Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 26 (2000) 695-708
15. N. Fotaki, In vitro release data vs. in vivo canine data for the prediction of gastrointestinal absorption of drug, Ph.D Thesis, National & Kapodistrian University of Athens, Athens, Greece, 2004.
16. Ramadan M.A., and Tawashi R. The effect of hydrodynamic conditions and delivery orifice size on the rate of drug release from the elementary osmotic pump system. Drug Dev. Ind. Pharm. 13 (1987) 235-248
17. Ijzerman A.P., Bultsma T., Timmerman H., and Zaagsma J. The ionization of b-adrenoceptor agonists: a method for unravelling ionization schemes. J. Pharm. Pharmacol. 36 (1984) 11-15
18. Forbes B., Shah A., Martin G.P., and Lansley A.B. The human bronchial epithelial cell line 16HBE14o - as a model system of the airways for studying drug transport. Int. J. Pharm. 257 (2003) 161-167
19. Lindenberg M., Kopp S., and Dressman J.B. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58 (2004) 265-278
20. Galia E., Horton J., and Dressman J.B. Albendazole generics - a comparative in vitro study. Pharm. Res. 16 (1999) 1871-1875
21. Galia E., Nicolaides E., Hoerter D., Loebenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
22. USP, United States Pharmacopeial Convention, Inc., The United States Pharmacopeia (USP 24), Rockville MD, 2000.
23. S. Klein, Biorelevant Dissolution Test Methods for Modified Release Dosage Forms, Doctoral Thesis, University of Frankfurt, Shaker-Verlag, Aachen, 2005.
24. Goldstein D.A., Tan Y.K., and Soldin S.J. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur. J. Pharmacol. 32 (1987) 631-634
25. Civiale C., Ritschel W.A., Shiu G.K., Aiache J.M., and Beyssac E. In vivo-in vitro correlation of salbutamol release from a controlled release osmotic pump delivery system. Methods Find. Exp. Clin. Pharmacol. 13 (1991) 491-498
26. Glanz S.A. Primer of Biostatistics. fourth ed. (1997), McGraw-Hill, Health Professions Division, New York
27. Nicolaides E., Symillides M., Dressman J.B., and Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18 (2001) 380-388
28. Billa N., Yuen K., and Khader M.A.A. Omar gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. Int. J. Pharm. 201 (2000) 109-120
29. Wilding I.R., Coupe A.J., and Davis S.S. The role of gamma scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 46 (2001) 103-124
30. Vertzoni M., Symillides M., Iliadis A., Nicolaides E., and Reppas C. Comparison of simulated cumulative drug vs. time data sets with indices. Eur. J. Pharm. Biopharm. 56 (2003) 421-428
31. Parojcić J., {Eth}urić Z., Jovanović M., Ibrić S., and Jovanovic D. Influence of dissolution media composition on drug release and in-vitro/in-vivo correlation for paracetamol matrix tablets prepared with novel carbomer polymers. J. Pharm. Pharmacol. 56 (2004) 735-741
32. Diebold S.M. Physiological parameters relevant to dissolution testing: hydrodynamic considerations. Pharmaceutical Dissolution Testing (2005), Taylor & Francis, London, UK 127-191
33. Cammarn S., and Sakr A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow-through cell dissolution. Int. J. Pharm. 201 (2000) 199-209